Metabolic Syndrome, Obesity
Conditions
Keywords
weight loss,metabolic risk, lifestyle intervention, homeostasis
Brief summary
In this single-blind, randomized trial, 395 eligible volunteers, who have higher metabolic syndrome (MetS) risk and aged 20-65 years, will be assigned to one of two smartphone-based lifestyle intervention arms: 1) Programmed-smartphone intervention or 2) Programmed-smartphone plus dietitian intervention. Before and after 6-month intervention, PhenFlex test (PFT) was performed to examine and quantify improved metabolic flexibility. This intervention trial will be conducted by researchers in Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences (CAS) collaborating with Zhejiang University affiliated Sir Run Run Shaw Hospital. The study protocol was approved by the Ethics Committees in Shanghai Institutes of Nutrition and Health, and in Sir Run Run Shaw Hospital. The main aims of this study are to determine 1) efficacy of lifestyle interventions with different intensity in reducing MetS and its risk factors; 2) improved metabolic responses or flexibility defined by PFT-based homeostasis index; and 3) major genetic and nongenetic determinants for the efficacy of interventions among high MetS risk Chinese.
Detailed description
Metabolic syndrome, a cluster of multiple metabolic disturbances, including central obesity, dyslipidemia, hypertension, and hyperglycemia, is associated with 2-5-fold heightened risks of CVD and T2D. Compelling evidence showed that lifestyle intervention is one of effective approaches for preventing and controlling cardiometabolic diseases. However, there were considerably variations among different interventions and different persons. With widely available smartphone and APP-connected wearable devises, it is possible to provide programmed nutrition and lifestyle education to help participants achieve intervention targets, and closely monitor compliance. However, few studies investigated the efficacy of lifestyle interventions with programmed smartphone and APP-connected wearable devises in MetS management. Moreover, since present disease-based diagnoses and biomarkers may not adequately define health status, the concept of re-redefining health has attracted growing attention. The phenotypic flexibility and PhenFlex test are one of approaches to measure individuals' adaptive capacity to maintain hemostatic condition after having a standardized challenge drinker. To date, the PFT has been studied among 10,000 subjects in western countries and few studies, if any, have conducted in Chinese who have different genetic background and dietary patterns. It remains to be established whether and to what extent that the PFT-based hemostatic index system can precisely evaluate the metabolic health in Chinese. In the current trial, 395 subjects with MetS risks were randomly assigned to either smartphone-based lifestyle intervention arms: 1) Programmed-smartphone intervention; or 2) Programmed-smartphone plus dietitian intervention. The intervention duration will be 6-month and then have 2-year follow-up. During starting and end of 6-month intervention, we included PFT during the physical examination hold in the Sir Run Run Shaw Hospital. All the subjects were given a standardized challenge drinker (75g glucose, 60 fat and 20g protein). Fasting and multiple postprandial time points samples (blood, t=0,1,3h) and urine and feces were collected to measure clinical and omics markers like metabolomics, gut microbiota and SNPs. Finally, the homeostasis index will be built to estimate improvement of individual metabolic health after the intervention. In conclusion, this study will provide scientific evidence and novel insights about the effectiveness of new intervention strategies and precise diagnostic and assessment system for cardiometabolic management.
Interventions
BEHAVIORALProgrammed smartphone intervention
Interactive programmed lifestyle education based on smartphone for six month
BEHAVIORALProgrammed smartphone plus dietitian intervention
Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
Sponsors
Sir Run Run Shaw Hospital
Chinese Academy of Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Volunteers at high metabolic risk aged 20-65 who didn't participate in other studies in 3 months before the current research, having a certain level of education and normal cognitive ability, taking good care of himself/herself. MetS risk factors were identified by the definition proposed by the International Diabetes Federation criteria for Chinese adults. Participants should have central obesity (waist circumference ≥90 cm in men or ≥80 cm in women).
Exclusion criteria
* Fasting glucose\>7.0mmol/L after taking insulin or other blood glucose-lowering drugs * Diagnosed phase three hypertension or can't lowering SBP under 160mmHg after anti-hypertension drugs * Fasting blood TG≥ 5.7 mmol/L or fasting LDL-C≥ 4.9 mmol/L after taking lipid-lowering drugs * Pregnancy or lactation * Obvious drug changing in three months before research * History of drug or alcohol abuse or other substance abuse (Alcohol abuse is defined as more than 40 g/day of alcohol for woman, and more than 80g/day for man) * Severe kidney and liver diseases (blood biomarkers such as alt, serum creatinine is 1.5 times over the scope of normal setting) * Severe Gastrointestinal diseases (such as severe diarrhea, constipation, severe digestive tract inflammation, active peptic ulcer, acute cholecystitis, etc.) * Having surgeries within one year before research such as heart stents implanted surgery (expect for appendicitis or hernia operation) * Severe cardiovascular disease (e.g., heart failure, myocardial infarction, cerebral infarction, and acute myocarditis, severe arrhythmia, received the intervention therapy, etc.) * Cancer or receiving radiotherapy and chemotherapy within 5 years * Severe pituitary or thyroid diseases * Suffering from AIDS, hepatitis A, hepatitis B and other infectious diseases * Mental disorders or current use of antidepressants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight | Baseline and month 6 | Weight will be assessed by Seca-255 (ScalesGalore) during each visit ,weight will also be assessed by Bluetooth scale at home |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Waist circumference | Baseline and month 6 | Waist circumference will be assessed by Seca-201(ScalesGalore) during each visit |
| Blood pressure | Baseline and month 6 | Both systolic pressure and diastolic pressure will be assessed using electronic blood pressure monitor (Omron J750)during each visit and at home |
| Triglyceride | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Total cholesterol | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| LDL-C | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Body mass index (BMI) | Baseline and month 6 | Body mass index (BMI) will be assessed by Seca-201(ScalesGalore) during each visit |
| Glucose | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Metabolic Homeostasis Score | Baseline and month 6 | A metabolic homeostasis score is a composite score that includes aggregated changes in blood biomarkers (metabolites or biomarkers or index involved in carbohydrates metabolism such as glucose, C-peptide, Matsuda index etc.; metabolites or biomarkers involved in lipid metabolism such as high-density lipoprotein cholesterol, total cholesterol, triglyceride etc.; metabolites or biomarkers involved in protein/vitamin metabolism such as creatinine; inflammatory or cytokines such as interleukin-6 etc.; hormones; anthropometric measures etc.). The metabolic homeostasis score is a composite score, that is calculated by the average of the scores of above-mentioned features using a certain computational algorithm. The larger the metabolic homeostasis score is, the worse the homeostatic resilience of the person, and vice versa. |
| Body composition | Baseline and month 6 | Body composition will be assessed by InBody-720 multi-frequency bioelectrical impedance device. |
| Compliance | Whole 6-month intervention | Behavioral compliance will be assessed by wearable devices and bluetooth devices. |
| HDL-C | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adiponectin concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Metabolomics including profiling of free fatty acids and other metabolites | Baseline and month 6 | Metabolomics will be measured by LC-MS |
| Single nucleotide polymorphism (SNPs) | Baseline | Mutations at specific sites will be detected by gene chip |
| Gut microbiota 16S rDNA sequencing | Baseline and month 6 | Gut microbiota 16S rDNA will be sequenced |
| Glucagon | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Glucagon-like peptide-1 | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Aspartate transaminase | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| HbA1c | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Alanine aminotransferase | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Serum creatinine | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| γ-glutamyl transpeptidase | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Urine creatinine | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Urea nitrogen | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Uric acid | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Gastric inhibitory peptide | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| Insulin | Baseline and month 6 | Values at fasting and postprandial 60min and 3hours will be measured |
| E-selectin concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| P-selectin concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Vascular cell adhesion molecule-1(VCAM-1) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Intercellular adhesion molecule-1 (ICAM-1) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Amyloid A1(SAA1) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Tumor Necrosis Factor-α (TNF-α) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Interleukin-10(IL-10) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Interleukin-1b(IL-1b) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| C-reactive protein(CRP) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
| Retinol binding protein(RBP4) concentration | Baseline and month 6 | Concentration at fasting and postprandial 60min and 3hours will be measured |
Countries
China
Outcome results
None listed